AMENDMENTS TO THE CLAIMS

1. **(Canceled)**

2. **(Previously Presented)** A method of treating a patient to reduce or inhibit the growth of tumor cells in a cancer by inhibiting glycosylated tumor cell receptors comprising administering to a patient an antibody directed against a tumor-cell receptor associated glycosylation antigen, wherein said antibody inhibits MAPK activation in said tumor cells and thereby inhibits activated MAPK mediated cell division, and wherein said antibody does not inhibit said glycosylated receptor from binding to its ligand.

3. **(Previously Presented)** The method according to claim 2, further comprising chemotherapy treatment of said patient.

4. **(Previously Presented)** The method according to claim 2, wherein the tumor cells of said patient are resistant to chemotherapy.

5. **(Previously Presented)** The method according to claim 2, wherein said antibodies are administered for treating a minimal residual disease.

6. **(Previously Presented)** The method according to claim 2, wherein said antibodies inhibit a mitogenic stimulation of said tumor cells by the epidermal growth factor (EGF) and/or by heregulin.

7. **(Previously Presented)** The method according to claim 2, wherein said tumor cells express a receptor from the family of the EGF receptors, and wherein said antibodies promote a lysis of said tumor cells.

8. **(Previously Presented)** The method according to claim 2, wherein said antibody is directed against Lewis antigens.

9. **(Previously Presented)** The method according to claim 2, wherein said antibody is directed against an aberrant glycosylation.

10. **(Previously Presented)** The method according to claim 9, wherein said aberrant glycosylation is a Lewis x-, Lewis b- or Lewis-y-structure, sialyl-Tn, Tn antigen, GloboH, KH1, TF antigen or an alpha-1,3-galactosyl epitope.

11. **(Previously Presented)** The method according to claim 2, wherein said antibody is a monoclonal antibody.

12. **(Previously Presented)** The method according to claim 11, wherein said monoclonal antibody is a human, humanized, chimeric or murine antibody.

13. **(Previously Presented)** The method according to claim 2, wherein said antibody has an affinity to binding the EGF receptor with a dissociation constant of below a Kd value of 10^{-6} mol/l, or less is used.

14. **(Previously Presented)** The method according to claim 2, wherein said antibody is used in a dose of at least 50 mg.

15. **(Previously Presented)** The method according to claim 2, wherein said antibody is an antibody derivative which comprises at least the Fab-portion of an antibody and binds to a tumor-associated glycosylation.

16. **(Previously Presented)** The method according to claim 2, wherein said patient suffers from a cancer with tumor cells which express a receptor from the family of the EGF receptors.

17. - 18. **(Canceled)**

19. **(Previously Presented)** The method according to claim 2,wherein a body fluid or a tissue from a cancer patient is treated ex vivo.

20. **(Previously Presented)** The method according to claim 19, wherein the cancer patient is treated within the frame of a high dosage chemotherapy.

21. **(Previously Presented)** The method according to claim 19, wherein the body fluid, or the tissue, respectively, is derived from a patient at risk for a cancer disease.

22. - 26. **(Canceled)**

27. **(Previously Presented)** The method according to claim 2, wherein said antibody is a humanized antibody directed against Lewis Y antigen.

28. **(Previously Presented)** The method according to claim 27, wherein said antibody is administered in combination with a carrier.

29. **(Cancelled)**

30. **(Cancelled)**

31. **(Previously Presented)** The method of claim 13, wherein said Kd value is less than 10^{-7} mol/1.

32. **(Previously Presented)** The method of claim 13, where said Kd is less than 10^{-8} mol/1.

33. **(Previously Presented)** The method of claim 14, said dose is at least 100 mg and up to 2 g per patient.

34. **(Previously Presented)** The method of claim 14, wherein said dose at least 200 mg and up to 2 g per patient.

35. – 43. **(Cancelled)**

44. **(Previously Presented)** The method of claim 19, wherein said body fluid or said tissue is selected from the group consisting of an organ, bone marrow, blood and serum.

45. **(Previously Presented)** The method of claim 14, wherein said antibody is used at a dose of at least 100 mg per patient.

46. **(Previously Presented)** The method of claim 14, wherein said antibody is used at a dose of at least 200 mg, per patient.

47. **(Previously Presented)** The method of claim 14, wherein said antibody is used at a dose of at least 100 mg, per patient.

48. **(Cancelled)**